📰 Roche Group News
Roche Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Roche Group. Real-time updates on events, politics, business and more.
June 10, 2024
SMA patients in the long-term extension Evrysdi study maintained or improved key developmental skills over the five-year period, data shows.
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with...
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive
June 1, 2024
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive
May 31, 2024
The latest vaccine technology is being used to create personalised treatments that target the DNA of patients specific tumours.
May 29, 2024
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an...
May 29, 2024
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an oral